• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Concert Pharmaceutic (NQ: CNCE )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Mar 3, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Concert Pharmaceutic

    < Previous 1 2 3 4 5 Next >
    Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Why Concert Pharmaceuticals Stock Rocketed Higher This Week
    The company is changing hands in a deal worth at least $576 million. 
    Via The Motley Fool
    CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    India-Based Sun Pharma Scoops Up Concert Pharmaceuticals For $576M Plus Milestones
    Via Benzinga
    Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Concert Pharmaceuticals, Coeur Mining And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded lower, with the Dow Jones dropping around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Concert Pharmaceuticals's Return On Capital Employed Insights
    Via Benzinga
    Concert Pharma: Q3 Earnings Insights
    Concert Pharma (NASDAQ:CNCE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
    U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday. 
    Via Benzinga
    CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
    From Concert Pharmaceuticals
    Via Business Wire
    Recap: Concert Pharma Q2 Earnings
      Concert Pharma (NASDAQ:CNCE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Is Ardelyx is A Buy After Slip in Early 2022
    Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
    Via MarketBeat
    Exposures Product Safety
    Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
    From Concert Pharmaceuticals
    Via Business Wire
    Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded lower, with the Dow Jones tumbling more than 800 points on Tuesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
    Upgrades 
    Via Benzinga
    Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Recap Of Monday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.